Fate Therapeutics, Inc. (NASDAQ:FATE), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ProTmune™ for the reduction of incidence and severity of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). In addition, the Company announced that its multi-center, randomized, controlled Phase 1/2 clinical trial of ProTmune in adult subjects with hematologic malignancies is open for patient enrollment.
Fate Therapeutics, Inc. (NASDAQ:FATE)’s stock on 20 June traded at beginning with a price of $1.90 and when day-trade ended the stock finally moved up 19.05% to end at $2.00. Fate Therapeutics, Inc. (NASDAQ:FATE)’s showed weekly performance of 12.36%.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock. In addition, Paratek expects to grant the underwriters of the offering a 30-day option to purchase up
... read more at: http://www.benchmarkmonitor.com/fate-therapeutics-inc-nasdaqfate-receives-fda-fast-track-designation-for-protmune-paratek-pharmaceuticals-nasdaqprtk-allergan-nyseagn-india-globalization-capital-nysemktigc-vivus-na/1868775/